CNS5:Pleomorphic xanthoastrocytoma: Difference between revisions
| Line 194: | Line 194: | ||
|D, P, T | |D, P, T | ||
|Yes (WHO CNS5, NCCN) | |Yes (WHO CNS5, NCCN) | ||
|Specific for PXA, actionable with BRAF/MEK inhibitors; rarely found in diffuse astrocytomas. Favorable prognostic marker<ref>{{Cite journal|last=Kim|first=Young Zoon|last2=Kim|first2=Chae-Yong|last3=Lim|first3=Do Hoon|date=2022-04|title=The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO|url=https://pubmed.ncbi.nlm.nih.gov/35545827|journal=Brain Tumor Research and Treatment|volume=10|issue=2|pages=83–93|doi=10.14791/btrt.2022.0001|issn=2288-2405|pmc=9098981|pmid=35545827}}</ref> | |Specific for PXA, actionable with BRAF/MEK inhibitors; rarely found in diffuse astrocytomas. Favorable prognostic marker<ref name=":2">{{Cite journal|last=Kim|first=Young Zoon|last2=Kim|first2=Chae-Yong|last3=Lim|first3=Do Hoon|date=2022-04|title=The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO|url=https://pubmed.ncbi.nlm.nih.gov/35545827|journal=Brain Tumor Research and Treatment|volume=10|issue=2|pages=83–93|doi=10.14791/btrt.2022.0001|issn=2288-2405|pmc=9098981|pmid=35545827}}</ref> | ||
|- | |- | ||
|TERT | |TERT | ||
| Line 203: | Line 203: | ||
|P | |P | ||
|Yes (WHO CNS5) | |Yes (WHO CNS5) | ||
|Associated with anaplastic progression, poor recurrence-free survival, and adverse prognosis in high-grade PXA | |Associated with anaplastic progression, poor recurrence-free survival, and adverse prognosis in high-grade PXA<ref name=":2" /> | ||
|- | |- | ||
|IDH1/IDH2 | |IDH1/IDH2 | ||